WeMed Secures ￥300M in Series D Funding

(VCBeat) Apr. 22, 2021 -- Recently, Beijing WeMed Medical Equipment Co., Ltd. ("WeMed"）has closed more than 300 million yuan in Series D financing, led by Lake Bleu Capital, with participation from Suzhou Longmen Venture Capital, Everest Venture Capital, and the existing investor old Luxin Venture Capital Group. Haoyue Capital acted as the sole financial advisor in this transaction.

Proceeds from the latest round will be used for branding, the market promotion of the products that have obtained the approvals at home and abroad, and the clinical research of the surgical robot for interventional surgeries, and the improvement of the management of interventional therapy in the whole process.

WeMed is a Chinese enterprise specializing in interventional diagnosis and treatment solutions, with years of experience in the R&D and industrialization of digital angiography systems. Its vision is to create a professional brand in the field of interventional medicine. At the same time, through overseas mergers and acquisitions and other forms, WeMed is devoted to achieving the international strategic layout of product research and development, manufacturing and marketing.

WeMed has finished the development and production of interventional products such as the digital subtraction angiography (DSA) system, mobile angiography system, surgical C-arms, as well as the R&D of innovative interventional surgical robots. It is a domestic company of interventional diagnosis and treatment equipment with a full series of interventional solutions.

Lake Bleu Capital is a multi-billion dollar asset management platform operating in Hong Kong and Shanghai. The company specializes in healthcare investing in Asia/Greater China. Its clients include sovereign wealth funds, endowments & foundations, pension funds, and family offices globally. 

Lake Bleu Capital manages strategies through both public and private equity with a primary focus on mid-to late-stage investments.

Suzhou Longmen Venture Capital is a cutting-edge fund focusing on "innovative drugs and medical devices", with the vision of "helping Chinese pharmaceutical developer go global and give back to the society". The core members of the team have more than 25 years of industry background, with total investment reaching tens of billions of yuan.